El proceso inflamatorio como vínculo entre la aterosclerosis y el sistema inmunológico
Autores
Mauricio Vargas-Valverde
Resumen
La aterosclerosis es la principal causa de enfermedad cardiovascular. La inflamación media el desarrollo y ruptura de la placa de ateroma. El reclutamiento de células inflamatorias como monocitos, linfocitos, neutrófilos, y mastocitos en la pared de los vasos sanguíneos ocurre debido al daño que el estrés hemodinámico genera en el endotelio vascular. En la región subendotelial hay partículas oxidadas de lipoproteínas de baja densidad que son fagocitadas por los macrófagos, estos acumulan colesterol y se convierten en células espumosas. Los distintos tipos de células presentes en la placa de ateroma generan citoquinas proinfamatorias que permiten la quimiotaxis de leucocitos. El debilitamiento y ruptura de la placa ocurre debido a defectos en los mecanismos de resolución de la inflamación. En consecuencia, el material aterotrombótico sale al lumen del vaso sanguíneo y puede ocasionar un infarto en el miocardio o un accidente cerebrovascular.
Palabras clave
Inflamación, aterosclerosis, monocito, macrófago, célula espumosa, inmunidad innata, inmunidad adaptativa.Abstract
Atherosclerosis is the main cause of cardiovascular disease. Inflammation mediates the development and rupture of the atheromatous plaque. The recruitment of inflammatory cells such as monocytes, lymphocytes, neutrophils and mast cells in the wall of blood vessels occurs due to the damage that hemodynamic stress generates in the vascular endothelium. In the subendothelial region there are oxidized particles of low density lipoproteins that are phagocytosed by macrophages. These accumulate cholesterol and become foam cells. The different types of cells present in the atheromatous plaque generate proinfamatorias cytokines that allow the chemotaxis of leukocytes. The weakening and rupture of plaque occurs due to defects in the mechanisms of resolution of inflammation. As a result, the atherothrombotic material exits the lumen of the blood vessel and can cause a myocardial infarction or stroke.
Key words
Inflammation, atherosclerosis, monocyte, macrophage, foam cell, innate immunity, adaptive immunity.Texto completo
Referencias
1. Yang X, Li Y, Li Y, Ren X, Zhang X, Hu D, et al. Oxidative stress-mediated aterosclerosis: mechanisms and therapies. Frontiers in Physiology 2017; 8(600): 1-16.
2. Kindt T, Goldsby R, Osborne B. Inmunología de Kubby. 6ta ed. México: McGraw-Hill Interamericana; 2007. 3. Hansson G, Hermansson A. The immune system in atherosclerosis. Nature Immunology. 2011; 12(3): 204-212. 4. Fatkhullina A, Peshkova I, Koltsova E. The role of cytokines in the development of aterosclerosis. Biochemistry. 2016; 81(11): 1358-1370.
5. Boamponsem A. The role of inflammation in atherosclerosis. Advances in Applied Science Research. 2011; 2(4): 194-207. 6. Charo I, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nature Reviews. 2011; 10: 365-376. 7. Sanmarco L, Eberhardt N, Ponce N, Cano R, Bonacci G, Aoki M. New insigths into the immunobiology of mononuclear phagocytic cells and their relevance to the pathogenesis of cardiovascular diseases. Front. Immunol. 2018; 8(1921): 1-20. 8. Baldrighi M, Mallat Z, Li X. NLRP3 inflammasome pathways in aterosclerosis. Atherosclerosis. 2017; 267: 127-138. 9. Mullick A, Tobias P, Curtiss L. Toll-like receptors and atherosclerosis. Key contributors in disease and health? Immunologic Research. 2006; 34(3): 193-209. 10. Rader D. IL-1 and atherosclerosis: a murine twist to an evolving human story. The Journal of Clinical Investigation. 2012; 122(1): 27-30.
11. Karasawa T, Takahashi M. Role of NLRP3 Inflammasomes in atherosclerosis. J Atheroscler Thromb. 2017; 24: 443-451. 12. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nature Reviews Immunology. 2010; 10: 36-46. 13. Yurdagul A, Doran A, Cal B, Fredman G, Tabas I. Mechanisms and consequences of defective efferocytosis in atherosclerosis. Front. Cardiovasc. Med. 2018; 4(86): 1-10. 14. Elliott M, Koster K, Murphy P. Efferocytosis signaling in the regulation of macrophage inflammatory responses. J Immunol. 2017; 198(4): 1387-1394. 15. Parisi L, Gini E, Baci D, Tremolati M, Fanuli M, Bassani B, et al. Macrophage polarization in chronic inflammatory diseases: killers or builders? Journal of Immunology Research. 2018: 1-25.